Current Report Filing (8-k)
October 31 2022 - 7:12AM
Edgar (US Regulatory)
0001633932
false
A1
0001633932
2022-10-31
2022-10-31
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): October
31, 2022
ESSA Pharma Inc.
(Exact name of registrant as specified in its charter)
British Columbia, Canada
(State or other jurisdiction of incorporation) |
001-37410
(Commission File Number) |
47-2569713
(IRS Employer Identification No.) |
|
|
|
Suite 720, 999 West Broadway, Vancouver, British
Columbia, Canada
(Address of principal executive offices) |
V5Z 1K5
(Zip Code) |
Registrant’s telephone number, including area
code: (778) 331-0962
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of
each class |
Trading
Symbol(s) |
Name of
each exchange on which registered |
Common Shares, no par value |
EPIX |
Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure
On Monday October 31, 2022, ESSA Pharma Inc. (“ESSA”)
issued a press release announcing that Janssen Research and Development (“Janssen”) is suspending enrollment into the Phase
1 clinical study of EPI-7386 with apalutamide or EPI-7386 with abiraterone acetate plus prednisone in metastatic castration-resistant
prostate cancer patients as a result of operational recruitment challenges. A copy of the related press release is furnished as Exhibit
99.1 to this Current Report on Form 8-K
The information provided under this Item 7.01 (including
Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange
Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 |
Financial Statements and Exhibits. |
|
|
|
(d) Exhibits |
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
ESSA PHARMA INC. |
|
|
|
(Registrant) |
|
Date: October 31, 2022
|
|
By: |
/s/ David Wood |
|
|
|
|
Name: |
David Wood |
|
|
|
|
Title: |
Chief Financial Officer |
|
|
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Aug 2024 to Sep 2024
ESSA Pharma (NASDAQ:EPIX)
Historical Stock Chart
From Sep 2023 to Sep 2024